Search

Your search keyword '"Blinder, Victoria"' showing total 270 results

Search Constraints

Start Over You searched for: Author "Blinder, Victoria" Remove constraint Author: "Blinder, Victoria"
270 results on '"Blinder, Victoria"'

Search Results

1. The landscape of use of NCCN-guideline chemotherapy regimens in stage I-IIIA breast cancer in an integrated healthcare delivery system

4. Comparing the Effectiveness of Electronic Symptom Monitoring versus Usual Care in Improving Survival among Patients with Metastatic Cancer -- The PRO-TECT Trial

5. Patient factors associated with chemotherapy modifications: Results from the Optimal Breast Cancer Chemotherapy Dosing (OBCD) study.

11. Financial Toxicity Monitoring in a Randomized Controlled Trial of Patient-Reported Outcomes During Cancer Treatment (Alliance AFT-39)

17. Cancer-Related Care Costs and Employment Disruption: Recommendations to Reduce Patient Economic Burden as Part of Cancer Care Delivery

18. Timing of exercise therapy when initiating adjuvant chemotherapy for breast cancer: a randomized trial.

20. Supplementary Table S2 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study

21. Supplementary Figure S2 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study

22. Supplementary Materials and Methods from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study

24. Survivorship Care

26. A randomized controlled trial of routine financial toxicity screening via electronic patient-reported outcomes (AFT-39).

27. Oral Chemotherapy Metric Performance in Quality Oncology Practice Initiative Practices: Updated Trends and Analysis

29. Lymphedema therapy referral is associated with improved understanding of lymphedema prevention among breast cancer survivors

32. Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer

33. Risk factors for financial toxicity in patients with gynecologic cancer

35. Additional file 1 of An interactive mobile application versus an educational booklet to promote job retention in women undergoing adjuvant chemotherapy for breast cancer: a randomized controlled trial

39. Effects of patient-reported outcome assessment order

41. Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer

42. Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0

45. Racial and ethnic disparities among patients with breast cancer and COVID-19.

46. A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer.

48. Abstract SS2-05: Emerging from COVID-19 pandemic: Provider perspective on use of neoadjuvant endocrine therapy (NET) in early stage hormone receptor positive breast cancer

49. Improving outcomes for patients with Burkitt lymphoma and HIV

50. Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study

Catalog

Books, media, physical & digital resources